肺腺鳞癌的临床现状及研究进展  

Clinical status and research progress of adenosquamous carcinoma of the lung

作　　者：刘海波[1] 张诗杰[1] Liu Haibo;Zhang Shijie(Department of Thoracic Surgery,Peking University First Hospital,Beijing 100034,China)

机构地区：[1]北京大学第一医院胸外科,北京100034

出　　处：《中国综合临床》2022年第4期304-307,共4页Clinical Medicine of China

摘　　要：肺腺鳞癌作为肺癌中一种罕见的病理类型,既含有腺癌成分又含有鳞癌成分,且每一种成分至少占10%,较单纯的肺鳞癌及肺腺癌具有更高的恶性程度及侵袭性,预后较差。手术切除和化疗目前仍是肺腺鳞癌的主要治疗手段。分子靶向药物治疗和免疫治疗在非小细胞肺癌领域的巨大进展给肺腺鳞癌患者带来了新的希望。肺腺鳞癌中表面生长因子受体(epidermal growth factor receptor,EGFR)基因突变率和程序性死亡配体1(programmed cell death ligand 1,PD-L1)表达率也分别同鳞癌和腺癌相当。这意味着靶向治疗和免疫治疗可能会给肺腺鳞癌患者带来显著的获益。如何制定个体化治疗策略和进行全程管理将是未来研究的重点,需进一步探索。Adenosquamous carcinoma of the lung(ASC),a relatively rare subtype of non-small-cell lung cancer,is defined as a malignancy containing components of both lung adenocarcinoma(ADC)and lung squamous cell carcinoma(SCC),with each comprising at least 10%of the tumor.Comparing to pure ADC or SCC,ASC has stronger aggressiveness and poorer prognosis.Surgery and chemotherapy are the mainstay treatments for ASC currently.The great progress of targeted therapy and immunotherapy in non-small cell lung cancer(NSCLC)has given ASC patients new hope.The EGFR mutation frequency and PD-L1 expression rate are similar comparing ASC to ADC and SCC,which means the targeted therapy and immunotherapy could make promising benefits to ASC patients.How to make personal treatment strategy and conduct whole course management is the emphasis of future studies.

关 键 词：肺腺鳞癌 免疫检查点抑制剂 免疫治疗 靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]